List of Excipients in Branded Drug DUREZOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	DUREZOL	durezol	0065-9240	BORIC ACID
Alcon Laboratories Inc	DUREZOL	durezol	0065-9240	CASTOR OIL
Alcon Laboratories Inc	DUREZOL	durezol	0065-9240	EDETATE DISODIUM
Alcon Laboratories Inc	DUREZOL	durezol	0065-9240	GLYCERIN

Durezol Excipient Strategy, Patent Position, Generic Competition, and Commercial Opportunities

Last updated: September 25, 2026

Durezol is a preservative-free ophthalmic emulsion containing difluprednate 0.05%, a difluorinated corticosteroid used for postoperative ocular inflammation and pain and for endogenous anterior uveitis. Its commercial differentiation depends less on the active ingredient than on emulsion stability, ocular tolerability, multidose delivery, manufacturing control, and regulatory equivalence.

The core opportunity is a generic or lifecycle product that matches Durezol’s physical performance while improving comfort, bottle usability, unit economics, or distribution access. The principal technical barrier is reproducing the emulsion’s particle-size distribution, droplet stability, dose uniformity, and redispersibility without adding preservatives or changing the clinical performance profile.

What excipients are used in Durezol ophthalmic emulsion?

Durezol contains difluprednate 0.05% in a sterile ophthalmic emulsion. The inactive ingredients listed in the U.S. prescribing information are boric acid, castor oil, polysorbate 80, sodium citrate, sorbitol, water for injection, and sodium hydroxide for pH adjustment (Novartis, 2023).

Excipient	Primary formulation function	Commercial relevance
Castor oil	Oil phase and solvent for the lipophilic corticosteroid	Controls drug solubilization and emulsion structure
Polysorbate 80	Nonionic surfactant	Stabilizes oil droplets and supports dose uniformity
Boric acid	Buffer component	Supports pH control and ocular tolerability
Sodium citrate	Buffer component	Controls pH and aqueous-phase stability
Sorbitol	Tonicity agent	Helps bring osmolality toward the tear-fluid range
Sodium hydroxide	pH adjustment	Establishes the final formulation pH
Water for injection	Continuous aqueous phase	Provides the sterile vehicle

Durezol’s formulation does not rely on a conventional antimicrobial preservative. That characteristic is commercially important because preservative exposure can limit tolerability in patients receiving frequent dosing or having ocular-surface disease.

Why does Durezol use an emulsion rather than a suspension?

Difluprednate is highly lipophilic. An oil-in-water emulsion can incorporate the active ingredient into the oil phase while presenting an aqueous product that can be administered as an eye drop. The formulation approach can reduce the visual and dosing variability associated with poorly wetting crystalline suspensions.

The emulsion strategy creates several development requirements:

• Controlled oil-droplet size
• Stable surfactant coverage
• Minimal creaming or coalescence
• Consistent drug concentration throughout the bottle
• Low sedimentation or phase separation
• Acceptable drop size and ocular residence time
• Sterility throughout the labeled in-use period

A generic product that uses a different excipient system may still need to demonstrate comparable pharmaceutical performance and bioequivalence under the applicable FDA pathway.

How does each excipient support Durezol performance?

Castor oil and difluprednate solubilization

Castor oil is the defining vehicle component. It provides a lipophilic environment for difluprednate and contributes to the formulation’s emulsion architecture. Replacing castor oil with another oil may change:

• Drug solubility
• Droplet size
• Interfacial tension
• Release from the formulation
• Drop spreading across the ocular surface
• Ocular irritation
• Long-term chemical stability

A substitute oil could offer lower raw-material cost or improved stability, but it would create a higher regulatory burden because the formulation would no longer be a close excipient match.

Polysorbate 80 and emulsion stability

Polysorbate 80 reduces interfacial tension between the oil and aqueous phases. Its concentration must be balanced. Too little surfactant can cause coalescence or poor redispersibility. Excess surfactant can increase ocular irritation, interact with packaging, or contribute to degradation products.

Polysorbate 80 also has batch-to-batch variability linked to oxidation and peroxide formation. A manufacturer therefore needs controls for:

• Peroxide value
• Fatty-acid composition
• Water content
• Trace metals
• Oxidative degradation
• Supplier and lot consistency

These controls can become part of the manufacturing barrier even when the excipients are individually commoditized.

Boric acid, sodium citrate, and pH control

The boric acid and sodium citrate system provides pH control. Durezol’s labeled pH range is approximately 5.0 to 6.0. pH affects chemical stability, ocular comfort, preservative-free sterility strategy, and the ionization behavior of formulation components.

A generic manufacturer should treat buffer composition as a critical quality attribute rather than a simple inactive-ingredient substitution. Small changes can affect:

• Difluprednate degradation
• Emulsion droplet charge
• Surfactant behavior
• Ocular tolerability
• Container-closure compatibility

Sorbitol and osmolality

Sorbitol provides tonicity adjustment and may influence the formulation’s aqueous-phase properties. Ophthalmic products that are substantially hypertonic or hypotonic can cause stinging, tearing, or reflex blinking. A commercially viable alternative should target an osmolality compatible with ocular administration while preserving emulsion stability.

What FDA regulatory status does Durezol have?

Durezol was approved in the United States under NDA 022212 for:

1. Treatment of inflammation and pain associated with ocular surgery.
2. Treatment of endogenous anterior uveitis.

The product is a prescription ophthalmic emulsion containing difluprednate 0.05%. The label includes dosing instructions that differ by indication and clinical response (Novartis, 2023).

Regulatory item	Durezol status
Active ingredient	Difluprednate
Strength	0.05%
Dosage form	Ophthalmic emulsion
Route	Ophthalmic
U.S. application	NDA 022212
Approval pathway	New drug application
Preservative status	Preservative-free formulation
Main indications	Postoperative inflammation and pain; endogenous anterior uveitis
Typical packaging	Multidose ophthalmic bottle

The product is a corticosteroid. Labeling includes the standard risks associated with ophthalmic steroid therapy, including elevated intraocular pressure, delayed healing, infection risk, and cataract formation with prolonged use.

What patents protect Durezol and when does exclusivity expire?

Durezol’s commercial exclusivity has historically depended on the combination of active-ingredient patents, formulation claims, use claims, FDA regulatory exclusivity, and any pediatric extension. The relevant legal position is not determined by the active ingredient alone.

The FDA Orange Book is the controlling public source for listed patents and exclusivity associated with approved drug products. Patent listings can change through delisting, expiration, litigation outcomes, or administrative updates (U.S. Food and Drug Administration, 2024).

Rights category	Relevance to Durezol
Difluprednate composition patents	May cover the active compound or compound class
Ophthalmic formulation patents	May cover emulsion composition, excipient ratios, or physical properties
Method-of-use patents	May cover treatment of ocular inflammation or specific administration regimens
Manufacturing patents	May cover emulsification, sterilization, or processing conditions
FDA exclusivity	Can delay ANDA approval independently of patent expiration
Orange Book listings	Determine the patents an ANDA applicant must address

Exact patent expiration dates should be taken from the current Orange Book and the underlying patent records. A patent’s expiration date may differ from the date on which commercial generic entry is possible because of pediatric extensions, patent-term adjustments, terminal disclaimers, litigation stays, or settlement agreements.

Has Durezol faced Paragraph IV challenges?

An ANDA applicant seeking approval before expiration of an Orange Book-listed patent may file a Paragraph IV certification. The applicant must notify the patent holder and NDA holder. A timely patent-infringement action can trigger a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory exceptions and court developments (U.S. Food and Drug Administration, 2024).

For Durezol, the relevant commercial questions are:

• Whether any listed formulation or method patents remain unexpired
• Whether a generic applicant has filed a Paragraph IV certification
• Whether litigation was filed within the statutory notice period
• Whether the parties reached a licensed or delayed-entry settlement
• Whether any 30-month stay has expired or been terminated
• Whether FDA approval remains blocked by regulatory exclusivity

A Paragraph IV filing does not establish that the generic will launch. The applicant can prevail in litigation, obtain a settlement date, amend its certification, or delay commercial launch for business reasons.

What formulation patents could protect a Durezol generic strategy?

The strongest formulation claims would generally cover measurable properties rather than a broad list of common excipients. Potential claim categories include:

Emulsion composition claims

These may define:

• Difluprednate concentration
• Castor-oil concentration
• Polysorbate 80 concentration
• Buffer system
• Tonicity agent
• pH and osmolality
• Absence of preservatives

Composition claims can be vulnerable if the claimed ranges are obvious combinations of known ophthalmic formulation components.

Physical-property claims

A formulation patent may define:

• Mean droplet diameter
• Droplet-size distribution
• Zeta potential
• Viscosity
• Redispersibility
• Phase-separation limits
• Drug-content uniformity

These claims can be harder to design around if the physical properties are directly tied to clinically relevant performance. They can also be difficult to enforce if the properties vary by test method or sampling location.

Manufacturing claims

Process claims could cover:

• Order of excipient addition
• High-shear emulsification
• Homogenization pressure
• Temperature control
• Sterile filtration or aseptic processing
• Filling conditions
• Container-closure handling

Manufacturing claims may create practical barriers, but enforcement can be difficult when the process is performed inside a generic manufacturer’s facility.

How strong is the Durezol patent estate?

The patent estate is likely strongest where it links the excipient system to a defined pharmaceutical performance profile. A broad claim covering difluprednate in a conventional ophthalmic vehicle is more exposed to invalidity and design-around arguments than a narrow claim directed to a specific preservative-free emulsion with defined stability and dose-uniformity characteristics.

Patent feature	Relative strategic strength
Broad difluprednate composition claim	Lower if compound protection has expired
Preservative-free emulsion	Moderate, depending on claim scope and prior art
Specific oil-surfactant ratio	Moderate to high if linked to stability or performance
Particle-size limitation	Moderate to high if analytically reproducible
Method of treating postoperative inflammation	Moderate, depending on claim breadth
Manufacturing process	Variable and difficult to monitor externally
Packaging or bottle configuration	Usually narrower but commercially useful

The commercial value of any remaining patent depends on whether it blocks an ANDA, whether a design-around is practical, and whether the product has sufficient revenue to justify litigation.

What generic entry risks exist for Durezol?

The highest-probability generic scenario is a difluprednate 0.05% ophthalmic emulsion that closely matches the reference product’s inactive ingredients and performance. A close formulation reduces development and bioequivalence risk but can increase exposure to formulation patent claims.

A design-around product may use a different oil, surfactant, buffer, or preservative strategy. It could reduce patent exposure but create greater regulatory and clinical-performance risk.

Generic strategy	Patent risk	Regulatory risk	Commercial attractiveness
Close excipient match	Higher	Lower	High
Alternative oil phase	Lower to moderate	Moderate to high	Moderate
Alternative surfactant	Lower to moderate	Moderate	Moderate
Preserved multidose product	Lower formulation overlap	High tolerability and labeling risk	Low to moderate
Unit-dose preservative-free product	Lower direct overlap	Moderate	High for specialty use
Suspension instead of emulsion	Potentially lower	High performance risk	Low unless clinically differentiated

The main commercial constraint is market size. Ophthalmic corticosteroids are competitive, price-sensitive products, and a generic may face rapid price erosion after launch.

What commercial opportunities exist for Durezol excipients?

Preservative-free multidose technology

Durezol already occupies a preservative-free position. A supplier or licensee could improve:

• Bottle sterility over the in-use period
• Tip protection
• Drop-size consistency
• Ease of priming
• Residual volume
• User handling

Advanced multidose systems can support premium positioning if the package improves adherence or reduces contamination risk.

Unit-dose packaging

Unit-dose vials could target:

• Postoperative centers
• Hospital formularies
• Short-duration treatment
• Patients with severe ocular-surface sensitivity
• Institutional settings where contamination control is prioritized

The disadvantages are higher packaging cost, greater material consumption, and potential inconvenience for outpatient patients.

Excipient-supplier opportunities

The most attractive supplier opportunities are qualified, ophthalmic-grade materials with better consistency and documentation:

• Low-peroxide polysorbate 80
• Controlled-composition castor oil
• Low-endotoxin sorbitol
• High-purity borate and citrate buffers
• Ready-to-use sterile excipient solutions
• Container-compatible surfactant systems

Excipient suppliers can create value through tighter specifications, regulatory support, dual sourcing, and stability data rather than through basic commodity pricing.

Lifecycle reformulation

Potential lifecycle products include:

• Lower-irritation emulsions
• Smaller-drop delivery systems
• Longer in-use shelf life
• Improved bottle emptying
• Unit-dose versions
• Combination products with other ophthalmic agents

Each change must preserve the clinical role of difluprednate and avoid creating a new tolerability or bioequivalence problem.

How does Durezol compare with competing ophthalmic corticosteroids?

Product	Active ingredient	Formulation	Preservative strategy	Commercial position
Durezol	Difluprednate 0.05%	Emulsion	Preservative-free	Potent steroid with differentiated emulsion
Pred Forte	Prednisolone acetate 1%	Suspension	Historically preserved	Established, lower-cost comparator
Lotemax	Loteprednol etabonate	Suspension or gel depending product	Product-specific	Lower-steroid-burden positioning
FML	Fluorometholone	Suspension or solution depending product	Product-specific	Older, lower-cost corticosteroid
Maxidex	Dexamethasone	Suspension or solution	Product-specific	Established corticosteroid alternative

Durezol’s excipient differentiation is strongest against suspension products because the emulsion can provide a distinct physical presentation and preservative-free profile. Its commercial vulnerability is greatest where prescribers and payers prioritize price over formulation attributes.

What manufacturing and intellectual-property barriers matter most?

The main manufacturing barriers are not the availability of the individual excipients. Castor oil, polysorbate 80, sorbitol, boric acid, citrate, and water for injection are broadly available. The barriers are process control and reproducibility.

Critical controls include:

1. Active solubilization in the oil phase.
2. Controlled emulsification and homogenization.
3. Droplet-size distribution.
4. Surfactant and oil-phase compatibility.
5. Sterile processing.
6. Container-closure integrity.
7. In-use stability.
8. Dose uniformity through the bottle’s final doses.
9. Control of oxidation, especially in polysorbate 80.
10. Demonstration of comparable ophthalmic performance.

Geographic supply-chain risk is concentrated in specialty-grade excipients, sterile filling capacity, and validated ophthalmic packaging. Dual sourcing is commercially important because a change in polysorbate 80 or castor-oil grade can alter stability even when the nominal excipient identity remains unchanged.

What is the likely revenue exposure and market opportunity?

Durezol-specific revenue is generally not disclosed separately in public filings when the product is included within a broader ophthalmology portfolio. The commercial value of a generic therefore depends on prescription volume, reimbursement, launch timing, number of approved competitors, wholesale acquisition price, and the ability to secure pharmacy and institutional contracts.

A practical opportunity ranking is:

Opportunity	Revenue potential	Execution risk
Standard generic difluprednate emulsion	Moderate	Moderate
Preservative-free unit-dose product	Moderate	Moderate to high
Premium multidose delivery system	Moderate	High
Excipient supply to multiple manufacturers	Moderate	Moderate
Reformulated low-irritation product	High if differentiated	High
Combination ophthalmic product	High if clinically justified	Very high

The most defensible commercial position is a product that combines regulatory similarity with a clear operational advantage, such as lower drop waste, stronger in-use sterility, improved comfort, or better institutional packaging.

Key Takeaways

• Durezol is a preservative-free difluprednate 0.05% ophthalmic emulsion.
• Castor oil solubilizes the lipophilic active ingredient, while polysorbate 80 stabilizes the oil-water interface.
• Boric acid, sodium citrate, sorbitol, and sodium hydroxide control pH and tonicity.
• The principal generic-development barrier is emulsion reproducibility, not raw-material availability.
• A close generic match lowers regulatory risk but may increase formulation-patent exposure.
• A design-around formulation reduces overlap risk but may require more extensive performance and equivalence work.
• Commercial opportunities include standard generic entry, preservative-free unit-dose packaging, improved multidose systems, and qualified ophthalmic excipient supply.
• Current Orange Book listings, Paragraph IV certifications, litigation, and settlement terms determine the practical timing of generic launch.
• Durezol-specific revenue exposure is difficult to isolate without product-level company disclosures.
• The strongest lifecycle strategy is a measurable formulation or delivery improvement that supports a clear clinical, adherence, or supply-chain advantage.

FAQs

Is Durezol a suspension or an emulsion?

Durezol is an ophthalmic emulsion. Its oil phase contains castor oil, which helps incorporate the lipophilic difluprednate active ingredient.

Is polysorbate 80 in Durezol safe for ophthalmic use?

Polysorbate 80 is used as a nonionic ophthalmic surfactant. Its concentration, impurity profile, oxidation level, and interaction with the container are important quality attributes.

Can a generic Durezol product use different excipients?

A generic may use different excipients if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and labeling. A meaningful excipient change can increase development and regulatory risk.

What is the best preservative-free alternative to Durezol?

The closest alternative is another difluprednate 0.05% ophthalmic emulsion with a comparable preservative-free formulation. Other corticosteroids may differ in potency, formulation, indication, and ocular-safety profile.

Are Durezol’s excipients patentable on their own?

The individual excipients are generally well-known materials. Patent value is more likely to arise from their combination, concentration ranges, emulsion properties, stability profile, manufacturing process, or use in a defined ophthalmic treatment.

References

1. Novartis Pharmaceuticals Corporation. (2023). Durezol (difluprednate ophthalmic emulsion) 0.05% prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2014). Guidance for industry: ANDAs for certain highly purified synthetic peptides. U.S. Department of Health and Human Services.

4. United States Pharmacopeia. (2024). USP-NF general chapters for ophthalmic preparations, emulsions, sterility, and pharmaceutical quality. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2023). Approved drug products and patent certifications under the Drug Price Competition and Patent Term Restoration Act. U.S. Department of Health and Human Services.